Background: The aim of this study was to assess the utility of ProGRP determinations in patients with selected cancer localization, during and after therapy.
Materials and methods: The study involved a reference group and a population of lung, breast, ovarian, and prostate cancer patients. ProGRP was evaluated using two-step chemiluminescent microparticle immunoassay (CMIA) manufactured by Abbott Diagnostics, and Architect i2000 analyzer.
Results: During follow-up of SCLC patients, an increased value for ProGRP was found in 51 % and for NSE only in 25.5 % of the patients, whereas in NSCLC patients, percentages with elevated ProGRP and CYFRA 21-1 were 8.6 % and 55.7 %, respectively. SCLC patients also had the highest AUC values for ProGRP. In other cancers, the frequency of elevated ProGRP results were as follows: 13.1 % - in breast cancer patients, 19.6 % - in ovarian cancer patients, and 15.1 % - in prostate cancer patients.
Conclusions: The presented study revealed that ProGRP is a tumor marker of choice in SCLC, because of its high diagnostic specificity in relation to the reference group and to the group with other malignancies.
DOI: Clin. Lab. 2010;56:527-534